Cytek Biosciences (CTKB) Research & Development (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Research & Development data on file, last reported at $9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 1.24% year-over-year to $9.6 million; the trailing twelve-month figure through Mar 2026 stood at $36.3 million (down 7.58% YoY), and the FY2025 full-year result was $36.5 million, down 7.45% from the prior year.
• Research & Development for Q1 2026 stood at $9.6 million, up from $9.0 million in the prior quarter.
• Across five years, Research & Development topped out at $12.1 million in Q2 2023 and bottomed at $8.0 million in Q1 2022.
• The 5-year median for Research & Development is $9.7 million (2025), against an average of $9.7 million.
• The widest annual swing landed in 2022, when Research & Development soared 57.54%; it then decreased 17.59% in 2024.
• A 5-year view of Research & Development shows it stood at $9.7 million in 2022, then increased by 11.51% to $10.9 million in 2023, then retreated by 10.54% to $9.7 million in 2024, then declined by 7.83% to $9.0 million in 2025, then advanced by 7.16% to $9.6 million in 2026.
• The last three Research & Development figures came in at $9.6 million (Q1 2026), $9.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.

Peer Comparison